Provided herein are non-naturally occurring self-assembling polypeptides for transferring nucleic acids and/or proteins to a cell, pharmaceutical compositions comprising such polypeptides, and methods for treatment comprising use of such compositions. The methods for producing polypeptide compositions may include combining in a solution, unassembled recombinant GAG-like proteins, nucleic acids and/or proteins in low salt conditions; and increasing the ionic strength of the solution.

An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.

Provided herein are non-naturally occurring self-assembling polypeptides for transferring nucleic acids and/or proteins to a cell, pharmaceutical compositions comprising such polypeptides, and methods for treatment comprising use of such compositions. The methods for producing polypeptide compositions may include combining in a solution, unassembled recombinant GAG-like proteins, nucleic acids and/or proteins in low salt conditions; and increasing the ionic strength of the solution.

An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.

Provided is an oncolytic virus, including an M protein and a G protein. The M protein includes amino acid substitutions at positions 51, 221, and 226 compared with an amino acid sequence as shown in SEQ ID NO: 1. The G protein includes at least one amino acid substitution compared with an amino acid sequence as shown in SEQ ID NO: 2. Further provided are an expression vector of the oncolytic virus, a virus production cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus, and a method for preparing the oncolytic virus, the expression vector of the oncolytic virus, the virus production cell, and/or the pharmaceutical composition, and an use thereof.

Provided are a recombinant oncolytic virus and a use thereof. The recombinant oncolytic virus includes an M protein and an antigen encoded by an exogenous gene, wherein the M protein includes the following site mutations compared to an amino acid sequence as shown in SEQ ID NO 1: mutating of methionine at position 51 into arginine (M51R); mutating of valine at position 221 into phenylalanine (V221F); and mutating of serine at position 226 into arginine (S226R). The recombinant oncolytic viruses provided have better infective ability and killing ability in vitro to abnormally proliferative (tumor) LLC cell and are all not easy to eliminate in the LLC cell, greatly reducing the infective ability of the recombinant oncolytic viruses to normal cells.

The present disclosure relates to methods for inhibiting the growth of a tumor in a patient in need thereof. The methods comprise administering to the patient an oncolytic virus in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., cemiplimab or a bioequivalent thereof) and optionally, a therapeutically effective amount of a CTLA-4 inhibitor (e.g., ipilimumab or a bioequivalent thereof). In some embodiments, the administration of the combination results in enhanced tumor inhibition as compared to administration of either antibody or the virus alone. In some embodiments, the oncolytic virus is a recombinant vesicular stomatitis virus (VSV), such as VV1.

Disclosed is a method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug. Specifically, the method includes the following steps: treating the tumor by using the recombinant oncolytic virus in combination with the small-molecule anticancer drug, wherein the small-molecule anticancer drug includes a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4/6, and a small-molecule anticancer drug targeting KRAS; and the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein after site-directed mutagenesis.